325 related articles for article (PubMed ID: 25962717)
1. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
Dienstmann R; Patnaik A; Garcia-Carbonero R; Cervantes A; Benavent M; Roselló S; Tops BB; van der Post RS; Argilés G; Skartved NJ; Hansen UH; Hald R; Pedersen MW; Kragh M; Horak ID; Braun S; Van Cutsem E; Tolcher AW; Tabernero J
Cancer Discov; 2015 Jun; 5(6):598-609. PubMed ID: 25962717
[TBL] [Abstract][Full Text] [Related]
2. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
Montagut C; Argilés G; Ciardiello F; Poulsen TT; Dienstmann R; Kragh M; Kopetz S; Lindsted T; Ding C; Vidal J; Clausell-Tormos J; Siravegna G; Sánchez-Martín FJ; Koefoed K; Pedersen MW; Grandal MM; Dvorkin M; Wyrwicz L; Rovira A; Cubillo A; Salazar R; Desseigne F; Nadal C; Albanell J; Zagonel V; Siena S; Fumi G; Rospo G; Nadler P; Horak ID; Bardelli A; Tabernero J
JAMA Oncol; 2018 Apr; 4(4):e175245. PubMed ID: 29423521
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
5. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.
Kojima T; Yamazaki K; Kato K; Muro K; Hara H; Chin K; Goddemeier T; Kuffel S; Watanabe M; Doi T
Cancer Sci; 2018 Oct; 109(10):3253-3262. PubMed ID: 30099818
[TBL] [Abstract][Full Text] [Related]
7. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
8. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.
Napolitano S; Martini G; Martinelli E; Belli V; Parascandolo A; Laukkanen MO; Sforza V; Morgillo F; Ciardiello D; Ciardiello F; Troiani T
Oncotarget; 2017 Sep; 8(40):67592-67604. PubMed ID: 28978055
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
Kubo A; Hashimoto H; Takahashi N; Yamada Y
World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
[TBL] [Abstract][Full Text] [Related]
13. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
14. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.
Machiels JP; Specenier P; Krauß J; Dietz A; Kaminsky MC; Lalami Y; Henke M; Keilholz U; Knecht R; Skartved NJ; Horak ID; Pamperin P; Braun S; Gauler TC
Cancer Chemother Pharmacol; 2015 Jul; 76(1):13-20. PubMed ID: 25952795
[TBL] [Abstract][Full Text] [Related]
15. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
[TBL] [Abstract][Full Text] [Related]
16. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
Modest DP; Jung A; Moosmann N; Laubender RP; Giessen C; Schulz C; Haas M; Neumann J; Boeck S; Kirchner T; Heinemann V; Stintzing S
Int J Cancer; 2012 Aug; 131(4):980-6. PubMed ID: 21960311
[TBL] [Abstract][Full Text] [Related]
17. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
Dienstmann R; Tabernero J
Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
